Analyzing Eloxx Pharmaceuticals (ELOX) and Its Competitors

Eloxx Pharmaceuticals (NASDAQ:ELOX) is one of 903 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare Eloxx Pharmaceuticals to similar companies based on the strength of its analyst recommendations, dividends, profitability, risk, institutional ownership, earnings and valuation.

Earnings & Valuation

This table compares Eloxx Pharmaceuticals and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Eloxx Pharmaceuticals	$6.36 million	-$5.99 million	-9.74
Eloxx Pharmaceuticals Competitors	$4.43 billion	$3.15 billion	547.15

Eloxx Pharmaceuticals’ peers have higher revenue and earnings than Eloxx Pharmaceuticals. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are owned by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for Eloxx Pharmaceuticals and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	1	0	2	1	2.75
Eloxx Pharmaceuticals Competitors	7586	13648	25433	998	2.42

Eloxx Pharmaceuticals currently has a consensus price target of $41.50, indicating a potential upside of 176.67%. As a group, “Pharmaceuticals” companies have a potential upside of 30.04%. Given Eloxx Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts clearly believe Eloxx Pharmaceuticals is more favorable than its peers.

Volatility & Risk

Eloxx Pharmaceuticals has a beta of -1862.26, indicating that its share price is 186,326% less volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals’ peers have a beta of -3.18, indicating that their average share price is 418% less volatile than the S&P 500.

Profitability

This table compares Eloxx Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
Eloxx Pharmaceuticals Competitors	-2,299.87%	-222.98%	-17.45%

Summary

Eloxx Pharmaceuticals beats its peers on 7 of the 13 factors compared.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.